These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 25646775)

  • 1. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
    Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
    PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.
    Seyyedi SS; Soleimani M; Yaghmaie M; Ajami M; Ajami M; Pourbeyranvand S; Alimoghaddam K; Akrami SM
    Tumour Biol; 2016 Apr; 37(4):4841-7. PubMed ID: 26526573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia.
    Ma QL; Wang JH; Yang M; Wang HP; Jin J
    J Transl Med; 2018 Mar; 16(1):68. PubMed ID: 29540187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy.
    Yang C; Shao T; Zhang H; Zhang N; Shi X; Liu X; Yao Y; Xu L; Zhu S; Cao J; Cheng H; Yan Z; Li Z; Niu M; Xu K
    J Transl Med; 2018 Oct; 16(1):267. PubMed ID: 30285885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
    Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
    Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a microRNA-mRNA Regulatory Network in
    Esa E; Hashim AK; Mohamed EHM; Zakaria Z; Abu Hassan AN; Mat Yusoff Y; Kamaluddin NR; Abdul Rahman AZ; Chang KM; Mohamed R; Subbiah I; Jamian E; Ho CS; Lim SM; Lau PC; Pung YF; Zain SM
    Genet Test Mol Biomarkers; 2021 Mar; 25(3):199-210. PubMed ID: 33734890
    [No Abstract]   [Full Text] [Related]  

  • 8. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
    Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.
    Bhayadia R; Krowiorz K; Haetscher N; Jammal R; Emmrich S; Obulkasim A; Fiedler J; Schwarzer A; Rouhi A; Heuser M; Wingert S; Bothur S; Döhner K; Mätzig T; Ng M; Reinhardt D; Döhner H; Zwaan CM; van den Heuvel Eibrink M; Heckl D; Fornerod M; Thum T; Humphries RK; Rieger MA; Kuchenbauer F; Klusmann JH
    J Clin Oncol; 2018 Apr; 36(10):1007-1016. PubMed ID: 29432078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.
    Zhang H; Zhang N; Wang R; Shao T; Feng Y; Yao Y; Wu Q; Zhu S; Cao J; Zhang H; Li Z; Liu X; Niu M; Xu K
    J Transl Med; 2019 Apr; 17(1):106. PubMed ID: 30935386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.
    Fu L; Fu H; Tian L; Xu K; Hu K; Wang J; Wang J; Jing H; Shi J; Ke X
    Oncotarget; 2016 Mar; 7(13):15828-39. PubMed ID: 26910834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Let-7a-3 hypomethylation is associated with favorable/intermediate karyotypes but not with survival in acute myeloid leukemia.
    Zhu XW; Yao DM; Wu DH; Wen XM; Yang J; Guo H; Yang L; Deng ZQ; Zhang YY; Qian W; Lin J; Qian J
    Tumour Biol; 2016 Jan; 37(1):491-501. PubMed ID: 26227220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
    He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
    Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.
    Niederwieser C; Kohlschmidt J; Volinia S; Whitman SP; Metzeler KH; Eisfeld AK; Maharry K; Yan P; Frankhouser D; Becker H; Schwind S; Carroll AJ; Nicolet D; Mendler JH; Curfman JP; Wu YZ; Baer MR; Powell BL; Kolitz JE; Moore JO; Carter TH; Bundschuh R; Larson RA; Stone RM; Mrózek K; Marcucci G; Bloomfield CD
    Leukemia; 2015 Mar; 29(3):567-75. PubMed ID: 25204569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
    Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
    Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.
    Marcucci G; Maharry KS; Metzeler KH; Volinia S; Wu YZ; Mrózek K; Nicolet D; Kohlschmidt J; Whitman SP; Mendler JH; Schwind S; Becker H; Eisfeld AK; Carroll AJ; Powell BL; Kolitz JE; Garzon R; Caligiuri MA; Stone RM; Bloomfield CD
    J Clin Oncol; 2013 Jun; 31(17):2086-93. PubMed ID: 23650424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients.
    Shibayama Y; Kondo T; Ohya H; Fujisawa S; Teshima T; Iseki K
    Oncol Rep; 2015 May; 33(5):2176-82. PubMed ID: 25759982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.
    Zhang TJ; Wu DH; Zhou JD; Li XX; Zhang W; Guo H; Ma JC; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Apr; 233(4):3274-3281. PubMed ID: 28884855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
    Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
    Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.